Covid-19: Pfizer vaccine efficacy was 52% after first dose and 95% after second dose, paper showsBMJ 2020; 371 doi: https://doi.org/10.1136/bmj.m4826 (Published 11 December 2020) Cite this as: BMJ 2020;371:m4826
- Elisabeth Mahase
- The BMJ
The Pfizer and BioNTech covid-19 vaccine may provide some early protection, starting 12 days after the first dose, the peer reviewed results of a phase III trial have found.
The study, published in the New England Journal of Medicine,1 found that vaccine efficacy between the first and second doses was 52% (95% credible interval 29.5% to 68.4%), with 39 cases of covid-19 in the vaccine group and 82 cases in the placebo group.
Seven or more days after the second dose, vaccine efficacy then rose to 95% (90.3% to 97.6%), with eight covid-19 cases reported in the vaccine group and 162 cases in the placebo group.
The vaccine has so far been approved in Canada …